We have located links that may give you full text access.
The small-molecule formyl peptide receptor biased agonist, Compound 17b, is a vasodilator and anti-inflammatory in mouse precision-cut lung slices.
British Journal of Pharmacology 2023 September 2
BACKGROUND AND PURPOSE: Pulmonary arterial hypertension (PAH), a rare but fatal disorder, is characterised by inflammation, vascular remodelling and vasoconstriction. Current vasodilator therapies reduce pulmonary arterial pressure (PAP) but not mortality. The G protein-coupled formyl peptide receptors (FPR) mediate vasodilatation and resolution of inflammation, actions likely to be beneficial in PAH. We investigated dilator and anti-inflammatory effects of the FPR biased agonist Compound 17b (Cmpd17b) in the pulmonary vasculature using mouse precision-cut lung slices (PCLS).
EXPERIMENTAL APPROACH: Using PCLS from 8-week-old male and female C57BL/6 mice, intrapulmonary arteries were pre-contracted with 5-HT for concentration-response curves to FPR agonists Cmpd17b and Cmpd43, and standard-of-care sildenafil, iloprost and riociguat. Cmpd17b-mediated relaxation was assessed ± FPR antagonists or pharmacological inhibitors, and in PCLS treated with TNF-α or LPS. Cytokine release into media from TNF-α- or LPS-treated PCLS ± Cmpd17b was determined.
KEY RESULTS: Cmpd17b elicited concentration-dependent vasodilation, with potencies of iloprost > Cmpd17b = riociguat > Cmpd43 = sildenafil. Cmpd17b was inhibited by the FPR1 antagonist Cyclosporin-H but not by inhibitors of sGC, NOS or COX. Under inflammatory conditions, the efficacy and potency of Cmpd17b were maintained, while iloprost and sildenafil were less effective. Additionally, Cmpd17b inhibited secretion of PAH-relevant cytokines via FPR2.
CONCLUSION AND IMPLICATIONS: Vasodilation to Cmpd17b, but not standard-of-care vasodilators, is maintained under inflammatory conditions, with additional inhibition of PAH-relevant cytokine release. Our study provides the first evidence that targeting FPR, using a biased agonist, simultaneously targets vascular function and inflammation, supporting the development of FPR-based pharmacotherapy to treat PAH.
EXPERIMENTAL APPROACH: Using PCLS from 8-week-old male and female C57BL/6 mice, intrapulmonary arteries were pre-contracted with 5-HT for concentration-response curves to FPR agonists Cmpd17b and Cmpd43, and standard-of-care sildenafil, iloprost and riociguat. Cmpd17b-mediated relaxation was assessed ± FPR antagonists or pharmacological inhibitors, and in PCLS treated with TNF-α or LPS. Cytokine release into media from TNF-α- or LPS-treated PCLS ± Cmpd17b was determined.
KEY RESULTS: Cmpd17b elicited concentration-dependent vasodilation, with potencies of iloprost > Cmpd17b = riociguat > Cmpd43 = sildenafil. Cmpd17b was inhibited by the FPR1 antagonist Cyclosporin-H but not by inhibitors of sGC, NOS or COX. Under inflammatory conditions, the efficacy and potency of Cmpd17b were maintained, while iloprost and sildenafil were less effective. Additionally, Cmpd17b inhibited secretion of PAH-relevant cytokines via FPR2.
CONCLUSION AND IMPLICATIONS: Vasodilation to Cmpd17b, but not standard-of-care vasodilators, is maintained under inflammatory conditions, with additional inhibition of PAH-relevant cytokine release. Our study provides the first evidence that targeting FPR, using a biased agonist, simultaneously targets vascular function and inflammation, supporting the development of FPR-based pharmacotherapy to treat PAH.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app